Suppr超能文献

目标样原发性肝脏恶性肿瘤在慢性肝病中的应用:利用术前 MRI 表现和临床因素预测术后生存。

Targetoid Primary Liver Malignancy in Chronic Liver Disease: Prediction of Postoperative Survival Using Preoperative MRI Findings and Clinical Factors.

机构信息

Department of Radiology, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.

Department of Radiology, Ajou University Hospital, Suwon, Korea.

出版信息

Korean J Radiol. 2023 Mar;24(3):190-203. doi: 10.3348/kjr.2022.0560. Epub 2023 Jan 19.

Abstract

OBJECTIVE

We aimed to assess and validate the radiologic and clinical factors that were associated with recurrence and survival after curative surgery for heterogeneous targetoid primary liver malignancies in patients with chronic liver disease and to develop scoring systems for risk stratification.

MATERIALS AND METHODS

This multicenter retrospective study included 197 consecutive patients with chronic liver disease who had a single targetoid primary liver malignancy (142 hepatocellular carcinomas, 37 cholangiocarcinomas, 17 combined hepatocellular carcinoma-cholangiocarcinomas, and one neuroendocrine carcinoma) identified on preoperative gadoxetic acid-enhanced MRI and subsequently surgically removed between 2010 and 2017. Of these, 120 patients constituted the development cohort, and 77 patients from separate institution served as an external validation cohort. Factors associated with recurrence-free survival (RFS) and overall survival (OS) were identified using a Cox proportional hazards analysis, and risk scores were developed. The discriminatory power of the risk scores in the external validation cohort was evaluated using the Harrell C-index. The Kaplan-Meier curves were used to estimate RFS and OS for the different risk-score groups.

RESULTS

In RFS model 1, which eliminated features exclusively accessible on the hepatobiliary phase (HBP), tumor size of 2-5 cm or > 5 cm, and thin-rim arterial phase hyperenhancement (APHE) were included. In RFS model 2, tumors with a size of > 5 cm, tumor in vein (TIV), and HBP hypointense nodules without APHE were included. The OS model included a tumor size of > 5 cm, thin-rim APHE, TIV, and tumor vascular involvement other than TIV. The risk scores of the models showed good discriminatory performance in the external validation set (C-index, 0.62-0.76). The scoring system categorized the patients into three risk groups: favorable, intermediate, and poor, each with a distinct survival outcome (all log-rank < 0.05).

CONCLUSION

Risk scores based on rim arterial enhancement pattern, tumor size, HBP findings, and radiologic vascular invasion status may help predict postoperative RFS and OS in patients with targetoid primary liver malignancies.

摘要

目的

本研究旨在评估和验证与慢性肝病患者根治性手术切除后异质性靶形原发性肝恶性肿瘤的复发和生存相关的影像学和临床因素,并建立风险分层评分系统。

材料与方法

这是一项多中心回顾性研究,纳入了 197 例慢性肝病患者,这些患者术前经钆塞酸增强 MRI 检查发现单个靶形原发性肝恶性肿瘤(142 例肝细胞癌、37 例胆管细胞癌、17 例肝细胞癌-胆管细胞癌混合癌和 1 例神经内分泌癌),并于 2010 年至 2017 年间手术切除。其中 120 例患者为研究队列,77 例患者来自另一机构作为外部验证队列。采用 Cox 比例风险分析确定与无复发生存(RFS)和总生存(OS)相关的因素,并建立风险评分。在外部验证队列中,通过 Harrell C 指数评估风险评分的判别能力。使用 Kaplan-Meier 曲线估计不同风险评分组的 RFS 和 OS。

结果

在排除仅在肝胆期(HBP)可获得的特征的 RFS 模型 1 中,纳入肿瘤大小为 2-5 cm 或 > 5 cm,以及薄边动脉期高增强(APHE)。在 RFS 模型 2 中,纳入肿瘤大小>5 cm、肿瘤静脉侵犯(TIV)和 HBP 低信号结节伴无 APHE。OS 模型纳入肿瘤大小>5 cm、薄边 APHE、TIV 和除 TIV 以外的肿瘤血管侵犯。模型的风险评分在外验证集具有良好的判别性能(C 指数,0.62-0.76)。评分系统将患者分为三个风险组:良好、中等和较差,每组的生存结果明显不同(所有对数秩检验 P<0.05)。

结论

基于边缘动脉增强模式、肿瘤大小、HBP 表现和影像学血管侵犯状态的风险评分可能有助于预测靶形原发性肝恶性肿瘤患者的术后 RFS 和 OS。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c9e/9971837/1f1f06a0b6e7/kjr-24-190-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验